Simple fluorescence assay for quantification of OSCS in heparin

被引:19
作者
Luehn, Susanne [1 ]
Schiemann, Simone [1 ]
Alban, Susanne [1 ]
机构
[1] Univ Kiel, Inst Pharmaceut, D-24118 Kiel, Germany
关键词
Heparin; Quantification; Counterfeit drugs; Quality assurance/control; OSCS; Fluorescence assay; OVERSULFATED CHONDROITIN SULFATE; ADVERSE CLINICAL EVENTS; CONTAMINANT;
D O I
10.1007/s00216-010-3867-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In 2008, heparin contaminated with oversulfated chondroitin sulfate (OSCS) penetrated the worldwide market and was associated with severe adverse effects. Feasible and reliable methods to test heparin for adulteration are needed. The objective was to develop a simple approach based on a microplate assay for quantification of heparin and sulfated glycans using the fluorescent heparin sensor polymer-H (polymer-H assay). However, both heparin and OSCS concentration-dependently increase the fluorescence intensity (FI) of polymer-H, so that OSCS in heparin cannot be detected. The idea was a two-step procedure including, first, separation of heparin by degradation with heparinase I, and then measurement of the remaining OSCS. To achieve complete heparin (unfractionated heparin (UFH), enoxaparin) degradation, several conditions (e.g. incubation time and heparinase I concentration) were optimized by using the aXa assay for monitoring. Defined UFH/OSCS mixtures incubated in this way showed a concentration-dependent FI increase in the polymer-H assay (lambda ((em)) 330 nm, lambda ((ex)) 510 nm). The sensitivity was unexpectedly high with an LOD/LOQ of 0.5%/0.6% OSCS content in heparin. Further experiments testing UFH/OSCS mixtures in the aXa assay confirmed our hypothesis: OSCS inhibits heparinase I resulting in incomplete heparin degradation and thus an additional FI increase of polymer-H by intact heparin. This two-step microplate fluorescence assay is a sensitive, rapid, and simple method for quantification of OSCS in heparin. In contrast with (1)H NMR and CE, neither expensive equipment nor much experience are required. It could be applied not only in the quality control of heparin, but also in clinical practice, to check the applied heparin preparation when a patient suffers any adverse effect.
引用
收藏
页码:673 / 680
页数:8
相关论文
共 25 条
[1]   Pharmacological strategies for inhibition of thrombin activity [J].
Alban, S. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (12) :1152-1175
[2]  
Alban S, 2008, HAMOSTASEOLOGIE, V28, P400
[3]  
ALBAN S, 2009, J THROMBOSIS HAEMOST, V7
[4]  
ALBAN S, 2010, PHARM ZTG, V12, P14
[5]   Prothrombin Time for Detection of Contaminated Heparins [J].
Alban, Susanne ;
Luehn, Susanne .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (25) :2732-2734
[6]  
[Anonymous], 2008, European Pharmacopoeia, V6th
[7]   Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products [J].
Bairstow, Shawn ;
McKee, Jeff ;
Nordhaus, Mark ;
Johnson, Richard .
ANALYTICAL BIOCHEMISTRY, 2009, 388 (02) :317-321
[8]   A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors [J].
Basche, Michele ;
Gustafson, Daniel L. ;
Holden, Scott N. ;
O'Bryant, Cindy L. ;
Gore, Lia ;
Witta, Samir ;
Schultz, Mary Kay ;
Morrow, Mark ;
Levin, Adrah ;
Creese, Brian R. ;
Kangas, Michael ;
Roberts, Kaye ;
Nguyen, Thu ;
Davis, Kat ;
Addison, Russell S. ;
Moore, Jane C. ;
Eckhardt, S. Gail .
CLINICAL CANCER RESEARCH, 2006, 12 (18) :5471-5480
[9]   Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy [J].
Beyer, T. ;
Diehl, B. ;
Randel, G. ;
Humpfer, E. ;
Schaefer, H. ;
Spraul, M. ;
Schollmayer, C. ;
Holzgrabe, U. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (01) :13-19
[10]   Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market [J].
Beyer, Tanja ;
Matz, Magnus ;
Brinz, Daniela ;
Raedler, Oliver ;
Wolf, Bernhard ;
Norwig, Jochen ;
Baumann, Knut ;
Alban, Susanne ;
Holzgrabe, Ulrike .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 40 (04) :297-304